Cited by 5,761Lung Cancer Treatments and MutationsLung Cancer Diagnosis and TreatmentLung Cancer Research Studies

The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.

Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer

Open access

Sandler, Alan, Gray, Robert, Perry, Michael C., Brahmer, Julie, Schiller, Joan H., Dowlati, Afshin, Lilenbaum, Rogerio, Johnson, David H.·2006·New England Journal of Medicine

DOI 10.1056/nejmoa061884

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: Bevacizumab, a monoclonal antibody against vascular endothelial growth factor, has been shown to benefit patients with a variety of cancers. METHODS: Between July 2001 and April 2004, the Eastern Cooperative Oncology Group (ECOG) conducted a randomized study in which 878 patients with recurrent or advanced non-small-cell lung cancer (stage IIIB or IV) were assigned to chemotherapy with paclitaxel and carboplatin alone (444) or paclitaxel and carboplatin plus bevacizumab (434). Chemotherapy was administered every 3 weeks for six cycles, and bevacizumab was administered every 3 weeks until disease progression was evident or toxic effects were intolerable. Patients with squamous-cell tumors, brain metastases, clinically significant hemoptysis, or inadequate organ function or performance status (ECOG performance status, >1) were excluded. The primary end point was overall survival. RESULTS: The median survival was 12.3 months in the group assigned to chemotherapy plus bevacizumab, as compared with 10.3 months in the chemotherapy-alone group (hazard ratio for death, 0.79; P=0.003). The median progression-free survival in the two groups was 6.2 and 4.5 months, respectively (hazard ratio for disease progression, 0.66; P<0.001), with corresponding response rates of 35% and 15% (P<0.001). Rates of clinically significant bleeding were 4.4% and 0.7%, respectively (P<0.001). There were 15 treatment-related deaths in the chemotherapy-plus-bevacizumab group, including 5 from pulmonary hemorrhage. CONCLUSIONS: The addition of bevacizumab to paclitaxel plus carboplatin in the treatment of selected patients with non-small-cell lung cancer has a significant survival benefit with the risk of increased treatment-related deaths. (ClinicalTrials.gov number, NCT00021060.)

Integrity signals

Registry

Crossref · 10.1056/nejmoa061884

Cites

24 of 24 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

The hallmarks of cancer
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968
The biology of VEGF and its receptors
Ferrara, N., Gerber, H.-P., & LeCouter, J. (2003) · Nature Medicine · doi:10.1038/nm0603-669 · Cited by 9,591
Comparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung Cancer
Schiller, J. H., Harrington, D., Belani, C. P., Langer, C., Sandler, A., Krook, J., Zhu, J., & Johnson, D. H. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011954 · Cited by 4,955
Self-citation
What Is the Evidence That Tumors Are Angiogenesis Dependent?
Folkman, J. (1990) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/82.1.4 · Cited by 4,509
Cancer Statistics, 2005
Jemal, A., Murray, T., Ward, E., Samuels, A., Tiwari, R. C., Ghafoor, A., Feuer, E. J., & Thun, M. J. (2005) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.55.1.10 · Cited by 4,186
COMPARISON OF FOUR CHEMOTHERAPY REGIMENS FOR ADVANCED NON-SMALL-CELL LUNG CANCER
Chiller, J. O. H. S., Arrington, D. A. H., Elani, C. H. P. B., Anger, C., Andler, A. L. S., Rook, J. A. K., Hu, J., & Ohnson, D. A. H. J. (2002) · Cited by 3,730
Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo
Kim, K. J., Li, B., Winer, J., Armanini, M., Gillett, N., Phillips, H. S., & Ferrara, N. (1993) · Nature · doi:10.1038/362841a0 · Cited by 3,605
Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy
Jain, R. K. (2001) · Nature Medicine · doi:10.1038/nm0901-987 · Cited by 2,184
Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer
Willett, C. G., Boucher, Y., di Tomaso, E., Duda, D. G., Munn, L. L., Tong, R. T., Chung, D. C., Sahani, D. V., Kalva, S. P., Kozin, S. V., et al. (2004) · Nature Medicine · doi:10.1038/nm988 · Cited by 1,985

Flagged first, then by citations

Show all 24 references

Research works printed but not linked: 4

Brown LF, 1993, Cancer Res, 53, 4727
Kabbinavar FF, 1995, Proc Am Assoc Cancer Res, 36, 488
Borgstrom P, 1999, Anticancer Res, 19, 4203
Miller KD, 2005, Breast Cancer Res Treat, 94, S6

Sorted by citations

Items 601–700 of 1,018

Targeting synovial neoangiogenesis in rheumatoid arthritis
Leblond, A., Allanore, Y., & Avouac, J. (2017) · Autoimmunity Reviews · doi:10.1016/j.autrev.2017.04.005 · Cited by 115
LncRNA NKX2‐1‐AS1 promotes tumor progression and angiogenesis via upregulation of SERPINE1 expression and activation of the VEGFR‐2 signaling pathway in gastric cancer
Teng, F., Zhang, J., Chen, Y., Shen, X., Su, C., Guo, Y., Wang, P., Shi, C., Lei, M., Cao, Y., et al. (2021) · Molecular Oncology · doi:10.1002/1878-0261.12911 · Cited by 116
Bevacizumab toxicities and their management in ovarian cancer
Randall, L. M., & Monk, B. J. (2010) · Gynecologic Oncology · doi:10.1016/j.ygyno.2010.02.021 · Cited by 116
A preclinical and clinical review of aflibercept for the management of cancer
Gaya, A. M., & Tse, V. (2012) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2011.12.008 · Cited by 115
Intensive care in patients with lung cancer: a multinational study
Soares, M., Toffart, A., Timsit, J., Burghi, G., Irrazábal, C., Pattison, N. A., Tobar, E. A., Almeida, B. F. C., Silva, U. V. A., Azevedo, L. C. P., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu234 · Cited by 115
Pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced non–small cell lung cancer without tumor PD‐L1 expression: A pooled analysis of 3 randomized controlled trials
Borghaei, H., Langer, C. J., Paz‐Ares, L., Rodríguez‐Abreu, D., Halmos, B., Garassino, M. C., Houghton, B., Kurata, T., Cheng, Y., Lin, J., et al. (2020) · Cancer · doi:10.1002/cncr.33142 · Cited by 115
Plasma Cytokine and Angiogenic Factor Profiling Identifies Markers Associated with Tumor Shrinkage in Early-Stage Non–Small Cell Lung Cancer Patients Treated with Pazopanib
Nikolinakos, P. G., Altorki, N. K., Yankelevitz, D. F., Tran, H. T., Yan, S., Rajagopalan, D., Bordogna, W., Ottesen, L. H., & Heymach, J. V. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-2533 · Cited by 114
Management of cardiac toxicity in patients receiving vascular endothelial growth factor signaling pathway inhibitors
Steingart, R. M., Bakris, G. L., Chen, H. X., Chen, M., Force, T. L., Ivy, S. P., Leier, C. V., Liu, G., Lenihan, D. J., Lindenfeld, J. M., et al. (2012) · American Heart Journal · doi:10.1016/j.ahj.2011.10.018 · Cited by 114
Acquired resistance to targeted therapies in NSCLC: Updates and evolving insights
Meador, C. B., & Hata, A. N. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107522 · Cited by 119
When are ‘positive’ clinical trials in oncology truly positive?
Ocana, A., & Tannock, I. F. (2011) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djq463 · Cited by 110
The Introduction of Systematic Genomic Testing for Patients with Non–Small-Cell Lung Cancer
Cardarella, S., Ortiz, T. M., Joshi, V. A., Butaney, M., Jackman, D. M., Kwiatkowski, D. J., Yeap, B. Y., Janne, P. A., Lindeman, N. I., & Johnson, B. E. (2012) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3182745bcb · Cited by 112
50 Years of Progress in the Systemic Therapy of Non–Small Cell Lung Cancer
Wakelee, H. A., Kelly, K. L., & Edelman, M. J. (2014) · American Society of Clinical Oncology Educational Book · doi:10.14694/edbook_am.2014.34.177 · Cited by 114
The paradoxical effect of bevacizumab in the therapy of malignant gliomas
Thompson, E. M., Frenkel, E. P., & Neuwelt, E. A. (2010) · Neurology · doi:10.1212/wnl.0b013e318204a3af · Cited by 112
Strategies for modern biomarker and drug development in oncology
Smith, A. D., Roda, D., & Yap, T. A. (2014) · Journal of Hematology & Oncology · doi:10.1186/s13045-014-0070-8 · Cited by 112
Strategies to overcome acquired resistance to EGFR TKI in the treatment of non-small cell lung cancer
Gao, J., Li, H.-R., Jin, C., Jiang, J., & Ding, J. (2019) · Clinical & Translational Oncology · doi:10.1007/s12094-019-02075-1 · Cited by 113
Broadening the clinical use of platinum drug–based chemotherapy with new analogues
Kèlland, L. R. (2007) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.16.7.1009 · Cited by 112
A Trial-Based Assessment of the Cost-Utility of Bevacizumab and Chemotherapy versus Chemotherapy Alone for Advanced Non-Small Cell Lung Cancer
Goulart, B. H. L., & Ramsey, S. D. (2011) · Value in Health · doi:10.1016/j.jval.2011.04.004 · Cited by 112
Treatment in advanced colorectal cancer: what, when and how?
Chau, I., & Cunningham, D. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6605061 · Cited by 115
Efficacy and Safety of Bevacizumab-Based Therapy in Elderly Patients with Advanced or Recurrent Nonsquamous Non-small Cell Lung Cancer in the Phase III BO17704 Study (AVAiL)
Leighl, N. B., Zatloukal, P., Mezger, J. M., Ramlau, R., Moore, N., Reck, M., & Manegold, C. (2010) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181f49c22 · Cited by 111
Randomised, non-comparative phase II study of weekly docetaxel with cisplatin and 5-fluorouracil or with capecitabine in oesophagogastric cancer: the AGITG ATTAX trial
on behalf of the Australasian Gastro-Intestinal Trials Group, Tebbutt, N. C., Cummins, M. M., Sourjina, T., Strickland, A. H., van Hazel, G., Ganju, V., Gibbs, D. D., Stockler, M. R., Gebski, V., et al. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605522 · Cited by 109
Cancer of Unknown Primary Site
Morris, G. J., Greco, F. A., Hainsworth, J. D., Engstrom, P. F., Scialla, S. J., Jordan, W. E., & Thomas, L. C. (2010) · Seminars in Oncology · doi:10.1053/j.seminoncol.2010.03.009 · Cited by 111
Antiangiogenic Strategies on Defense: On the Possibility of Blocking Rebounds by the Tumor Vasculature after Chemotherapy
Shaked, Y., & Kerbel, R. S. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0905 · Cited by 111
Randomized Phase II Trial of Bevacizumab or Temsirolimus in Combination With Chemotherapy for First Relapse Rhabdomyosarcoma: A Report From the Children’s Oncology Group
Mascarenhas, L., Chi, Y.-Y., Hingorani, P., Anderson, J. R., Lyden, E. R., Rodeberg, D. A., Indelicato, D. J., Kao, S. C.-S., Dasgupta, R. A., Spunt, S. L., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.00576 · Cited by 111
Angiogenesis inhibition as a therapeutic strategy in non-small cell lung cancer (NSCLC).
Hall, R. D., Le, T. M., Haggstrom, D. E., & Gentzler, R. D. (2015) · PubMed · doi:10.3978/j.issn.2218-6751.2015.06.09 · Cited by 110
A phase I/II trial of enzastaurin in patients with recurrent high-grade gliomas
Kreisl, T. N., Kotliarova, S. E., Butman, J. A., Albert, P. S., Kim, L., Musib, L. C., Thornton, D., & Fine, H. A. (2010) · Neuro-Oncology · doi:10.1093/neuonc/nop042 · Cited by 109
Biologically Targeted Cancer Therapy and Marginal Benefits: Are We Making Too Much of Too Little or Are We Achieving Too Little by Giving Too Much?
Fojo, T., & Parkinson, D. R. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1277 · Cited by 110
Angiogenesis and Anti-Angiogenic Therapy in Gastric Cancer
Nienhüser, H., & Schmidt, T. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms19010043 · Cited by 110
Vascular Endothelial Growth Factor Expression in Ovarian Cancer: A Model for Targeted Use of Novel Therapies?
Duncan, T. J., Al‐Attar, A., Rolland, P., Scott, I., Deen, S., Liu, D. T. Y., Spendlove, I., & Durrant, L. G. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1888 · Cited by 110
Lung Cancer: Are we up to the Challenge?
Esposito, L., Conti, D., Ailavajhala, R., Khalil, N., & Giordano, A. (2010) · Current Genomics · doi:10.2174/138920210793175903 · Cited by 110
Erlotinib plus bevacizumab in previously treated patients with malignant pleural mesothelioma
Jackman, D. M., Kindler, H. L., Yeap, B. Y., Fidias, P. M., Salgia, R., Lucca, J. V., Morse, L. K., Ostler, P. A., Johnson, B. E., & Janne, P. A. (2008) · Cancer · doi:10.1002/cncr.23617 · Cited by 109
Salvage gamma knife stereotactic radiosurgery followed by bevacizumab for recurrent glioblastoma multiforme: a case–control study
Park, K.-J., Kano, H., Iyer, A., Liu, X., Niranjan, A., Flíckinger, J. C., Lieberman, F. S., Lunsford, L. D., & Kondziolka, D. S. (2011) · Journal of Neuro-Oncology · doi:10.1007/s11060-011-0744-9 · Cited by 109
Adverse Events Associated with Anti-EGFR Therapies for the Treatment of Metastatic Colorectal Cancer
Fakih, M., & Vincent, M. D. (2010) · Current Oncology · doi:10.3747/co.v17is1.615 · Cited by 152
Minichromosome Maintenance Protein 7 is a potential therapeutic target in human cancer and a novel prognostic marker of non-small cell lung cancer
Toyokawa, G., Masuda, K., Daigo, Y., Cho, H., Yoshimatsu, M., Takawa, M., Hayami, S., Maejima, K., Chino, M., Field, H. I., et al. (2011) · Molecular Cancer · doi:10.1186/1476-4598-10-65 · Cited by 112
VEGF-targeted cancer therapeutics—paradoxical effects in endocrine organs
Cao, Y. (2014) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2014.114 · Cited by 109
Cancer therapy and cardiovascular risk: focus on bevacizumab
Economopoulou, P., Kentepozidis, N. K., Kotsakis, A. P., & Kapiris, I. (2015) · Cancer Management and Research · doi:10.2147/cmar.s77400 · Cited by 108
How to make the best use of immunotherapy as first-line treatment of advanced/metastatic non-small-cell lung cancer
Peters, S., Reck, M., Smit, E. F., Mok, T. S. K., & Hellmann, M. D. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz109 · Cited by 108
Mice expressing a humanized form of VEGF-A may provide insights into the safety and efficacy of anti-VEGF antibodies
Gerber, H., Wu, X., Yu, L., Wiesmann, C., Liang, X. H., Lee, C. V., Fuh, G., Olsson, C., Damico, L. A., Xie, D., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0611492104 · Cited by 109
Phase I/II Study of Inhaled Doxorubicin Combined with Platinum-Based Therapy for Advanced Non–Small Cell Lung Cancer
Otterson, G. A., Villalona-Calero, M. A., Hicks, W. J., Pan, X. J., Ellerton, J. A., Gettinger, S. N., & Murren, J. R. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-3015 · Cited by 108
Myeloid-derived suppressor cells contribute to A2B adenosine receptor-induced VEGF production and angiogenesis in a mouse melanoma model
Sorrentino, C., Miele, L., Porta, A., Pinto, A., & Morello, S. (2015) · Oncotarget · doi:10.18632/oncotarget.4393 · Cited by 112
Integrating Surgery with Targeted Therapies for Renal Cell Carcinoma: Current Evidence and Ongoing Trials
Bex, A., Jonasch, E. W., Kırkalı, Z., Méjean, A., Mulders, P., Oudard, S. M., Patard, J., Powles, T. B., Poppel, H. V., & Wood, C. G. (2010) · European Urology · doi:10.1016/j.eururo.2010.08.029 · Cited by 107
Combining Immune Checkpoint Inhibitors with Anti-Angiogenic Agents
Ciciola, P., Cascetta, P., Bianco, C., Formisano, L., & Bianco, R. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9030675 · Cited by 113
Bcl-2 Orchestrates a Cross-talk between Endothelial and Tumor Cells that Promotes Tumor Growth
Kaneko, T., Zhang, Z., Mantellini, M. G., Karl, E., Zeitlin, B. D., Verhaegen, M. E., Soengas, M. S., Lingen, M. W., Strieter, R. M., Núñez, G., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-1497 · Cited by 107
Aflibercept (AVE0005): an alternative strategy for inhibiting tumour angiogenesis by vascular endothelial growth factors
Chu, Q. S.-C. (2009) · Expert Opinion on Biological Therapy · doi:10.1517/14712590802666397 · Cited by 108
Exploiting the Cancer Genome: Strategies for the Discovery and Clinical Development of Targeted Molecular Therapeutics
Yap, T. A., & Workman, P. (2011) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010611-134532 · Cited by 107
Prognostic Impact of MiR-155 in Non-Small Cell Lung Cancer Evaluated by in Situ Hybridization
Dønnem, T., Eklo, K., Berg, T., Sørbye, S. W., Lønvik, K., Al‐Saad, S., Al-Shibli, K. I., Andersen, S., Stenvold, H., Bremnes, R. M., et al. (2011) · Journal of Translational Medicine · doi:10.1186/1479-5876-9-6 · Cited by 106
Reporting of Serious Adverse Drug Reactions of Targeted Anticancer Agents in Pivotal Phase III Clinical Trials
Šeruga, B., Sterling, L., Wang, L. E., & Tannock, I. F. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.31.9624 · Cited by 110
Body Mass Index and Its Association with Clinical Outcomes for Advanced Non–Small-Cell Lung Cancer Patients Enrolled on Eastern Cooperative Oncology Group Clinical Trials
Dahlberg, S. E., Schiller, J. H., Bonomi, P., Sandler, A. B., Brahmer, J. R., Ramalingam, S. S., & Johnson, D. H. (2013) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31829cf942 · Cited by 106
Self-citation
Simultaneous Targeting of Tumor Antigens and the Tumor Vasculature Using T Lymphocyte Transfer Synergize to Induce Regression of Established Tumors in Mice
Chinnasamy, D., Tran, E., Yu, Z., Morgan, R. A., Restifo, N. P., & Rosenberg, S. A. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3913 · Cited by 108
Growth factor receptors and related signalling pathways as targets for novel treatment strategies of hepatocellular cancer
Höpfner, M., Schuppan, D., & Scherübl, H. (2008) · World Journal of Gastroenterology · doi:10.3748/wjg.14.1 · Cited by 106
Expression of IL-32 in human lung cancer is related to the histotype and metastatic phenotype.
Sorrentino, C., & Carlo, E. D. (2009) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200903-0400oc · Cited by 100
Controlling angiogenesis in breast cancer: A systematic review of anti-angiogenic trials
Mackey, J. R., Kerbel, R. S., Gelmon, K. A., McLeod, D., Chia, S., Rayson, D., Verma, S., Collins, L. L., Paterson, A. H. G., Robidoux, A., et al. (2012) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2011.12.002 · Cited by 104
R-CHOP with or without bevacizumab in patients with previously untreated diffuse large B-cell lymphoma: final MAIN study outcomes
Seymour, J. F., Pfreundschuh, M., Trněný, M., Sehn, L. H., Catalano, J., Csinady, E., Moore, N., Coiffier, B., & on behalf of the MAIN Study Investigators (2014) · Haematologica · doi:10.3324/haematol.2013.100818 · Cited by 105
Surfactant-based drug delivery systems for treating drug-resistant lung cancer
Kaur, P., Garg, T., Rath, G., Murthy, R. S. R., & Goyal, A. K. (2014) · Drug Delivery · doi:10.3109/10717544.2014.935530 · Cited by 106
PCA-1/ALKBH3 Contributes to Pancreatic Cancer by Supporting Apoptotic Resistance and Angiogenesis
Yamato, I., Sho, M., Shimada, K., Hotta, K., Ueda, Y., Yasuda, S., Shigi, N., Konishi, N., Tsujikawa, K., & Nakajima, Y. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-0328 · Cited by 105
Prognostic and Predictive Blood-Based Biomarkers in Patients with Advanced Pancreatic Cancer: Results from CALGB80303 (Alliance)
Nixon, A. B., Pang, H., Starr, M. D., Friedman, P. N., Bertagnolli, M. M., Kindler, H. L., Goldberg, R. M., Venook, A. P., & Hurwitz, H. I. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0926 · Cited by 104
A review of the management of elderly patients with non-small-cell lung cancer
Blanco, R., Maestu, I., de la Torre, M. G., Cassinello, A., & Nuñez, I. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu268 · Cited by 106
First‐line atezolizumab in addition to bevacizumab plus chemotherapy for metastatic, nonsquamous non–small cell lung cancer: A United States–based cost‐effectiveness analysis
Wan, X., Luo, X., Tan, C., Zeng, X., Zhang, Y., & Peng, L. (2019) · Cancer · doi:10.1002/cncr.32368 · Cited by 106
pH-sensitive multi-drug liposomes targeting folate receptor β for efficient treatment of non-small cell lung cancer
Park, Y. I., Kwon, S., Lee, G., Motoyama, K., Kim, M. W., Lin, M., Niidome, T., Choi, J. H., & Lee, A. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.12.011 · Cited by 108
Decoding tumor angiogenesis: pathways, mechanisms, and future directions in anti-cancer strategies
Liu, X., Zhang, J., Yi, T., Li, H., Tang, X., Liu, D., Wu, D., & Li, Y. (2025) · Biomarker Research · doi:10.1186/s40364-025-00779-x · Cited by 125
Sex Differences in the Drug Therapy for Oncologic Diseases
Schmetzer, O., & Flörcken, A. (2012) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-30726-3_19 · Cited by 104
Phase 1 First-in-Human Trial of the Vascular Disrupting Agent Plinabulin(NPI-2358) in Patients with Solid Tumors or Lymphomas
Mita, M. M., Spear, M. A., Yee, L., Mita, A. C., Heath, E. I., Papadopoulos, K. P., Federico, K. C., Reich, S. D., Romero, O., Malburg, L., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1096 · Cited by 105
Phase II Trial of Gefitinib in Combination with Bevacizumab as First-Line Therapy for Advanced Non–Small Cell Lung Cancer with Activating EGFR Gene Mutations: The Okayama Lung Cancer Study Group Trial 1001
Ichihara, E., Hotta, K., Nogami, N., Kuyama, S., Kishino, D., Fujii, M., Kozuki, T., Tabata, M., Harada, D., Chikamori, K., et al. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000434 · Cited by 105
A Phase II, Randomized, Double-blind, Placebo-controlled Multicenter Trial of Endostar in Patients With Metastatic Melanoma
Cui, C., Mao, L., Chi, Z., Si, L., Sheng, X., Kong, Y., Li, S., Lian, B., Gu, K., Tao, M., et al. (2013) · Molecular Therapy · doi:10.1038/mt.2013.79 · Cited by 102
Survival benefit with erlotinib maintenance therapy in patients with advanced non-small-cell lung cancer (NSCLC) according to response to first-line chemotherapy
Coudert, B. P., Ciuleanu, T., Park, K., Wu, Y.-L. L. C., Giaccone, G., Brugger, W., Gopalakrishna, P., & Cappuzzo, F. (2011) · Annals of Oncology · doi:10.1093/annonc/mdr125 · Cited by 104
Targeting the vasculature in hepatocellular carcinoma treatment: Starving versus normalizing blood supply
Liu, K., Zhang, X., Xu, W., Chen, J., Yu, J. Q., Gamble, J. R., & McCaughan, G. W. (2017) · Clinical and Translational Gastroenterology · doi:10.1038/ctg.2017.28 · Cited by 104
Emerging strategies in cancer therapy combining chemotherapy with immunotherapy
Luo, Q., Zhang, L., Luo, C., & Jiang, M. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.04.017 · Cited by 106
Angiogenesis and antiangiogenic therapy in non-Hodgkin's lymphoma
Ruan, J., Hajjar, K. A., Rafii, S., & Leonard, J. P. (2008) · Annals of Oncology · doi:10.1093/annonc/mdn666 · Cited by 106
Large cell carcinoma of the lung: clinically oriented classification integrating immunohistochemistry and molecular biology
Rossi, G., Mengoli, M. C., Cavazza, A., Nicoli, D., Barbareschi, M., Cantaloni, C., Papotti, M. G., Tironi, A., Graziano, P., Paci, M., et al. (2013) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-013-1501-6 · Cited by 103
Efficacy and safety of bevacizumab in active brain metastases from non-small cell lung cancer
Braganca, K. C. D., Janjigian, Y. Y., Azzoli, C. G., Kris, M. G., Pietanza, M. C., Nolan, C. P., Omuro, A. M. P., Holodny, A. I., & Lassman, A. B. (2010) · Journal of Neuro-Oncology · doi:10.1007/s11060-010-0200-2 · Cited by 103
Effect of Prior Cancer on Outcomes in Advanced Lung Cancer: Implications for Clinical Trial Eligibility and Accrual
Laccetti, A. L., Pruitt, S. L., Xuan, L., Halm, E. A., & Gerber, D. E. (2015) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djv002 · Cited by 103
The Impact of Genomic Changes on Treatment of Lung Cancer
Cardarella, S., & Johnson, B. E. (2013) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201305-0843pp · Cited by 103
Safety of thalidomide and bevacizumab in patients with hereditary hemorrhagic telangiectasia
VASCERN-HHT, O. B. O., Buscarini, E., Botella, L. M., Geisthoff, U. W., Kjeldsen, A. D., Mager, H. J., Pagella, F., Suppressa, P., Zarrabeitia, R., Dupuis‐Girod, S., et al. (2019) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-018-0982-4 · Cited by 104
Conquering lung cancer: current status and prospects for the future
Pirker, R. (2020) · Pulmonology · doi:10.1016/j.pulmoe.2020.02.005 · Cited by 101
Risk of venous thromboembolism in lung cancer
Tesselaar, M. E. T., & Osanto, S. (2007) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0b013e328209413c · Cited by 103
Therapeutic Targeting of Tumor Growth and Angiogenesis with a Novel Anti-S100A4 Monoclonal Antibody
Hernández, J. L., Padilla, L., Plaza, S. D., Coll, T., Hervas, R., Adán, J., Masa, M., Mitjans, F., Martinez, J. M., Coma, S., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0072480 · Cited by 101
First-line bevacizumab combined with reduced dose interferon-α2a is active in patients with metastatic renal cell carcinoma
Melichar, B., Koralewski, P., Ravaud, A., Pluzanska, A., Sergio Bracarda, A., Szczylik, C. A., Chevreau, C., Filipek, M., Delva, R., Sevin, E., et al. (2008) · Annals of Oncology · doi:10.1093/annonc/mdn161 · Cited by 103
Bevacizumab and Breast Cancer: A Meta-Analysis of First-Line Phase III Studies and a Critical Reappraisal of Available Evidence
Rossari, J. R. F., Metzger, O., Paesmans, M., Saini, K. S., Gennari, A., de Azambuja, E., & Piccart, M. J. (2012) · Journal of Oncology · doi:10.1155/2012/417673 · Cited by 102
MicroRNA Signatures in Tumor Tissue Related to Angiogenesis in Non-Small Cell Lung Cancer
Dønnem, T., Fenton, C. G., Lønvik, K., Berg, T., Eklo, K., Andersen, S., Stenvold, H., Al-Shibli, K. I., Al‐Saad, S., Bremnes, R. M., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0029671 · Cited by 104
Nanoparticle Albumin Bound Paclitaxel in the Treatment of Human Cancer: Nanodelivery Reaches Prime-Time?
Cucinotto, I., Fiorillo, L., Gualtieri, S., Arbitrio, M., Ciliberto, D., Staropoli, N., Grimaldi, A., Luce, A., Tassone, P., Caraglia, M., et al. (2013) · Journal of Drug Delivery · doi:10.1155/2013/905091 · Cited by 105
Accuracy of Fine Needle Aspiration Cytology in the Pathological Typing of Non-small Cell Lung Cancer
Nizzoli, R., Tiseo, M., Gelsomino, F., Bartolotti, M., Majori, M., Ferrari, L., Filippo, M. D., Rindi, G., Silini, E. M., Guazzi, A., et al. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31820b86cb · Cited by 102
Antiangiogenic Therapies: Going beyond Their Limits
Moserle, L., Jiménez-Valerio, G., & Casanovas, O. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0199 · Cited by 105
Systemic therapy of advanced non-small cell lung cancer: Major-developments of the last 5-years
Čufer, T., Ovčariček, T., & O'Brien, M. E. R. (2012) · European Journal of Cancer · doi:10.1016/j.ejca.2012.11.021 · Cited by 104
Angiogenesis Inhibitors in NSCLC
Manzo, A., Montanino, A., Carillio, G., Costanzo, R., Sandomenico, C., Normanno, N., Piccirillo, M. C., Daniele, G., Perrone, F., Rocco, G., et al. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18102021 · Cited by 104
Pembrolizumab as First-Line Therapy for Metastatic Non-Small-Cell Lung Cancer
Reck, M. (2017) · Immunotherapy · doi:10.2217/imt-2017-0121 · Cited by 101
The biological functions and clinical applications of exosomes in lung cancer
Chen, R., Xu, X., Qian, Z., Zhang, C., Niu, Y., Wang, Z., Sun, J., Zhang, X., & Yu, Y. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03233-y · Cited by 105
Overcoming microenvironmental resistance to PD-1 blockade in genetically engineered lung cancer models
Martínez-Usatorre, A., Kadioglu, E., Boivin, G., Cianciaruso, C., Guichard, A., Torchia, B., Zangger, N., Nassiri, S., Keklikoglou, I., Schmittnaegel, M., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abd1616 · Cited by 107
Bevacizumab plus irinotecan in the treatment patients with progressive recurrent malignant brain tumours
Poulsen, H. S., Grunnet, K., Mau‐Sørensen, M., Olsen, P., Hasselbalch, B., Nelausen, K. M., Kosteljanetz, M., & Lassen, U. (2008) · Acta Oncologica · doi:10.1080/02841860802537924 · Cited by 102
Phase II study of temozolomide, thalidomide, and celecoxib for newly diagnosed glioblastoma in adults
Kesari, S., Schiff, D., Henson, J. W., Muzikansky, A., Gigas, D. C., Doherty, L. M., Batchelor, T. T., Longtine, J. A., Ligon, K. L., Weaver, S., et al. (2008) · Neuro-Oncology · doi:10.1215/15228517-2008-005 · Cited by 102
A phase II trial of single agent bevacizumab in patients with relapsed, aggressive non-Hodgkin lymphoma: Southwest oncology group study S0108
Stopeck, A., Unger, J. M., Rimsza, L. M., Bellamy, W. T., Iannone, M., Persky, D. O., LeBlanc, M. L., Fisher, R. I., & Miller, T. P. (2009) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190902856808 · Cited by 102
Involvement of Epithelial Cell Transforming Sequence-2 Oncoantigen in Lung and Esophageal Cancer Progression
Hirata, D., Yamabuki, T., Miki, D., Ito, T., Tsuchiya, E., Fujita, M., Hosokawa, M., Chayama, K., Nakamura, Y., & Daigo, Y. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1672 · Cited by 102
Systemic VEGF inhibition accelerates experimental atherosclerosis and disrupts endothelial homeostasis – implications for cardiovascular safety
Winnik, S. H., Lohmann, C., Siciliani, G., von Lukowicz, T., Kuschnerus, K., Kränkel, N., Brokopp, C. E., Enseleit, F., Michels, S., Ruschitzka, F. T., et al. (2013) · International Journal of Cardiology · doi:10.1016/j.ijcard.2013.03.010 · Cited by 103
Angiogenesis in cancer: Anti-VEGF escape mechanisms.
Prager, G. W., Poettler, M., Unseld, M., & Zielinski, C. C. (2012) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2218-6751.2011.11.02 · Cited by 101
Combined Inhibition of the VEGFR and EGFR Signaling Pathways in the Treatment of NSCLC
Pennell, N. A., & Lynch, T. J. (2009) · The Oncologist · doi:10.1634/theoncologist.2008-0276 · Cited by 100
Phase 1 Study of AMG 386, a Selective Angiopoietin 1/2–Neutralizing Peptibody, in Combination with Chemotherapy in Adults with Advanced Solid Tumors
Mita, A. C., Takimoto, C. H. M., Mita, M. M., Tolcher, A. W., Sankhala, K. K., Sarantopoulos, J., Valdivieso, M., Wood, L., Rasmussen, E., Sun, Y., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-3368 · Cited by 101
Randomised, double-blind trial of carboplatin and paclitaxel with daily oral cediranib or placebo in patients with advanced non-small cell lung cancer: NCIC Clinical Trials Group study BR29
Laurie, S. A., Solomon, B., Seymour, L., Ellis, P. M., Goss, G. D., Shepherd, F. A., Boyer, M. J., Arnold, A., Clingan, P. R., Laberge, F., et al. (2013) · European Journal of Cancer · doi:10.1016/j.ejca.2013.11.032 · Cited by 101
Tumor refractoriness to anti-VEGF therapy
Ribatti, D. (2016) · Oncotarget · doi:10.18632/oncotarget.8694 · Cited by 105
Effect of First-Line Treatment on Myeloid-Derived Suppressor Cells’ Subpopulations in the Peripheral Blood of Patients with Non–Small Cell Lung Cancer
Koinis, F., Vetsika, E., Aggouraki, D., Skalidaki, E., Koutoulaki, A., Gkioulmpasani, M., Georgoulias, V., & Kotsakis, A. P. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.04.026 · Cited by 102
The Combination of Immune Checkpoint Blockade and Angiogenesis Inhibitors in the Treatment of Advanced Non-Small Cell Lung Cancer
Ren, S., Xiong, X., You, H., Shen, J., & Zhou, P. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.689132 · Cited by 104
Crosstalk between angiogenesis and immune regulation in the tumor microenvironment
Kim, H. J., Ji, Y. R., & Lee, Y. M. (2022) · Archives of Pharmacal Research · doi:10.1007/s12272-022-01389-z · Cited by 105
Primary chemotherapy for newly diagnosed nonsmall cell lung cancer patients with synchronous brain metastases compared with whole‐brain radiotherapy administered first
Lee, D. H., Han, J., Kim, H. T., Yoon, S. J., Pyo, H. R., Cho, K. H., Shin, S., Yoo, H., Lee, S. H., & Lee, J. S. (2008) · Cancer · doi:10.1002/cncr.23526 · Cited by 101

Authors: Sandler, A., Gray, R., Perry, M. C., Brahmer, J., Schiller, J. H., Dowlati, A., Lilenbaum, R., & Johnson, D. H.
Affiliations: Vanderbilt University (US)
Dana-Farber Cancer Institute (US)
University of Missouri (US)
Johns Hopkins University (US)
University of Wisconsin–Madison (US)
University Hospitals of Cleveland (US)
ORCID: Sandler, Alan
Gray, Robert
Brahmer, Julie
Schiller, Joan H.
Dowlati, Afshin
Johnson, David H.
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2006-12-14
Volume: 355
Issue: 24
Pages: 2542-2550
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejmoa061884
OpenAlex: W2145835533
Cited by: 5,761
References: 24
Citations by year: 2026: 49 · 2025: 71 · 2024: 112 · 2023: 135 · 2022: 177 · 2021: 183 · 2020: 180 · 2019: 227 · 2018: 257 · 2017: 278 · 2016: 321 · 2015: 389 · 2014: 400 · 2013: 461 · 2012: 513
FWCI: 299.17
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
Funders: National Cancer Institute (U10CA066636, CA-23318, CA49957, U10CA016116, CA66636, U10CA012046, U10CA014548, CA-16116, CA14548, U10CA031946, CA21076, U10CA049957, U10CA021076, U10CA023318, U10CA021115, CA 21115, CA-31946, CA12046)
Topics: Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
Keywords: non-small cell lung cancer, bevacizumab, paclitaxel, carboplatin, combination chemotherapy, vascular endothelial growth factor inhibition, overall survival, progression-free survival, pulmonary hemorrhage
MeSH terms: Bevacizumab, Aged, Antibodies, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Non-Small-Cell Lung, Female, Humans, Lung Neoplasms, Male, Middle Aged, Carboplatin, Paclitaxel, Disease-Free Survival, Angiogenesis Inhibitors, Vascular Endothelial Growth Factor A, Kaplan-Meier Estimate, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks